Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26921663 | 0.87 | TDP1 (0.45) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL29509634 | 0.85 | HSPB1 (0.45) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL14333927 | 0.85 | PDK1 (0.48) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL12480460 | 0.85 | HSPB1 (0.45) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1342303 | 0.82 | ALDH1A1 (0.63) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL30072983 | 0.81 | TDP1 (0.60) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL11693495 | 0.81 | TDP1 (0.67) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8208233 | 0.80 | TDP1 (0.48) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL2841769 | 0.80 | TDP1 (0.48) | TDP1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL30126884 | 0.78 | PDK1 (0.48) | TDP1NPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3496715-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3496715-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| WO-2018034917-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-1021434-A2 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND USE | Krenitsky Pharmaceuticals, Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998012190-A2 | PHENOXATHIIN DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE | KRENITSKY PHARMACEUTICAL, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | CYP27A1, CYP7A1, CYP7B1 | TDP1 2108/4885NPC1 71/4885RAB9A 1271/4885 |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | TDP1 2263/4885NPC1 102/4885RAB9A 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.